NICE technology appraisal guidance
Issued: August 2008
TA153
Entecavir for the treatment of chronic hepatitis B
This is an extract from the guidance and may be misleading if read alone. The complete guidance is available at guidance.nice.org.uk/ta153
1 Guidance
This guidance does not apply to people with chronic hepatitis B who also have hepatitis C, hepatitis D or HIV.
1.1 Entecavir, within its marketing authorisation, is recommended as an option for the treatment of people with chronic HBeAg-positive or HBeAg-negative hepatitis B in whom antiviral treatment is indicated.